Continuous Glucose Monitoring System (CGMS) in Type 2 Diabetic Patients Inadequately Controlled by Metformine Monotherapy; Analyze of Glycemic Profile Before and After Association of Glimepiride
Phase 4
Completed
- Conditions
- Diabetes Mellitus
- Registration Number
- NCT00633425
- Lead Sponsor
- Sanofi
- Brief Summary
Analyse the glucose profile, based on continuous glucose monitoring by CGMS, in type 2 diabetics inadequately controlled by metformin, before and after the addition of Glimepiride.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
- Men or women aged 35 to 70 years
- Having given their consent
- Type 2 diabetics (HBA1c greater than 6.5%
- Fasting glycaemia greater than 1.40 g/l) not controlled by Metformin for at least 6 weeks.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Change in interstitial glucose levels between the observation and maintenance phases. The mean of 24 variations in average hourly glucose readings recorded by CGMS.
- Secondary Outcome Measures
Name Time Method HbA1c and fasting blood glucose levels. Measured in the observation and maintenance phases, and change between the two phases.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Glimepiride's impact on glycemic profiles in type 2 diabetes patients using CGMS?
How does the addition of Glimepiride to metformin compare to other sulfonylurea combinations in type 2 diabetes management?
Which biomarkers correlate with improved HbA1c outcomes after metformin-Glimepiride combination therapy in type 2 diabetes?
What are the potential adverse events associated with CGMS monitoring in type 2 diabetes patients on metformin-Glimepiride therapy?
How do newer GLP-1 receptor agonists compare to metformin-Glimepiride combinations in inadequately controlled type 2 diabetes?
Trial Locations
- Locations (1)
Sanofi-Aventis
🇫🇷Paris, France
Sanofi-Aventis🇫🇷Paris, France